The international researcher team led by the University of Boston found that the blocking of LSD1’s epigenetic regulator can activate the immune system to combat plaques of the oral cavity (PKKR). The results of the work published In International Journal of Oral Sciences (IJOM).
The PKKR is one of the leading causes of mortality of cancer diseases of the oral cavity and is critical for the success of early diagnosis treatment. So far, most studies have focused on the late stages of the disease, but the new study has been intensified in the early stage of the development of cancer and in the role of LSD1 enzyme (LEF-specific Democylase-1).
Scientists have found that LSD1 regulated marks marks, including stat3 and cdk7, and contributed to the progression of the disease. Using genetic and pharmacological approaches, including the experimental compound of the SP2509, researchers have suppressed LSD1 activity, which stops the development of precancerous lesions in laboratory animals (cats and rats).
The inhibition of LSD1 suppressed the immune response, causing a slowdown in tumor growth, the restoration of the activity of CD8+ T cells, and a decrease in CTLA4 protein level. The drugs that can prevent the transition of precanced conditions to malignant forms turned out to be particularly effective.
The authors of the study emphasize that the combination of LSD1 blockers with existing immunotherapy methods can significantly strengthen the antitumor immune response. According to scientists, this approach can change the paradigm of the treatment of head and neck cancer and other tumors with similar epigenetic disorders.
Previously Created Immune therapy to combat cancer in late stages.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.